Choline metabolism alteration: A focus on ovarian cancer

Marina Bagnoli, Anna Granata, Roberta Nicoletti, Balaji Krishnamachary, Zaver M. Bhujwalla, Rossella Canese, Franca Podo, Silvana Canevari, Egidio Iorio, Delia Mezzanzanica

Research output: Research - peer-reviewShort survey

Abstract

Compared with normal differentiated cells, cancer cells require a metabolic reprograming to support their high proliferation rates and survival. Aberrant choline metabolism is a fairly new metabolic hallmark reflecting the complex reciprocal interactions between oncogenic signaling and cellular metabolism. Alterations of the involved metabolic network may be sustained by changes in activity of several choline transporters as well as of enzymes such as choline kinase-alpha (ChoK-α) and phosphatidylcholine-specific phospholipases C and D. Of note, the net outcome of these enzymatic alterations is an increase of phosphocholine and total choline-containing compounds, a "cholinic phenotype" that can be monitored in cancer by magnetic resonance spectroscopy. This review will highlight the molecular basis for targeting this pathway in epithelial ovarian cancer (EOC), a highly heterogeneous and lethal malignancy characterized by late diagnosis, frequent relapse, and development of chemoresistance. Modulation of ChoK-α expression impairs only EOC but not normal ovarian cells, thus supporting the hypothesis that "cholinic phenotype" is a peculiar feature of transformed cells and indicating ChoK-α targeting as a novel approach to improve efficacy of standard EOC chemotherapeutic treatments.

LanguageEnglish (US)
Article number153
JournalFrontiers in Oncology
Volume6
Issue numberJUN
DOIs
StatePublished - Jun 22 2016

Fingerprint

Choline
Ovarian Neoplasms
Neoplasms
Ovarian epithelial cancer
Phenotype
Choline Kinase
Phospholipase D
Phosphorylcholine
Delayed Diagnosis
Metabolic Networks and Pathways
Magnetic Resonance Spectroscopy
Recurrence
Enzymes
Therapeutics
phosphatidylcholine-specific phospholipase C
choline transporter

Keywords

  • Antioxidant defense
  • Choline kinase
  • Ovarian cancer
  • Phosphocholine metabolism
  • Reversal of drug resistance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bagnoli, M., Granata, A., Nicoletti, R., Krishnamachary, B., Bhujwalla, Z. M., Canese, R., ... Mezzanzanica, D. (2016). Choline metabolism alteration: A focus on ovarian cancer. Frontiers in Oncology, 6(JUN), [153]. DOI: 10.3389/fonc.2016.00153

Choline metabolism alteration : A focus on ovarian cancer. / Bagnoli, Marina; Granata, Anna; Nicoletti, Roberta; Krishnamachary, Balaji; Bhujwalla, Zaver M.; Canese, Rossella; Podo, Franca; Canevari, Silvana; Iorio, Egidio; Mezzanzanica, Delia.

In: Frontiers in Oncology, Vol. 6, No. JUN, 153, 22.06.2016.

Research output: Research - peer-reviewShort survey

Bagnoli, M, Granata, A, Nicoletti, R, Krishnamachary, B, Bhujwalla, ZM, Canese, R, Podo, F, Canevari, S, Iorio, E & Mezzanzanica, D 2016, 'Choline metabolism alteration: A focus on ovarian cancer' Frontiers in Oncology, vol 6, no. JUN, 153. DOI: 10.3389/fonc.2016.00153
Bagnoli M, Granata A, Nicoletti R, Krishnamachary B, Bhujwalla ZM, Canese R et al. Choline metabolism alteration: A focus on ovarian cancer. Frontiers in Oncology. 2016 Jun 22;6(JUN). 153. Available from, DOI: 10.3389/fonc.2016.00153
Bagnoli, Marina ; Granata, Anna ; Nicoletti, Roberta ; Krishnamachary, Balaji ; Bhujwalla, Zaver M. ; Canese, Rossella ; Podo, Franca ; Canevari, Silvana ; Iorio, Egidio ; Mezzanzanica, Delia. / Choline metabolism alteration : A focus on ovarian cancer. In: Frontiers in Oncology. 2016 ; Vol. 6, No. JUN.
@article{6d17d54828ff4c749e5bffcd88706279,
title = "Choline metabolism alteration: A focus on ovarian cancer",
abstract = "Compared with normal differentiated cells, cancer cells require a metabolic reprograming to support their high proliferation rates and survival. Aberrant choline metabolism is a fairly new metabolic hallmark reflecting the complex reciprocal interactions between oncogenic signaling and cellular metabolism. Alterations of the involved metabolic network may be sustained by changes in activity of several choline transporters as well as of enzymes such as choline kinase-alpha (ChoK-α) and phosphatidylcholine-specific phospholipases C and D. Of note, the net outcome of these enzymatic alterations is an increase of phosphocholine and total choline-containing compounds, a {"}cholinic phenotype{"} that can be monitored in cancer by magnetic resonance spectroscopy. This review will highlight the molecular basis for targeting this pathway in epithelial ovarian cancer (EOC), a highly heterogeneous and lethal malignancy characterized by late diagnosis, frequent relapse, and development of chemoresistance. Modulation of ChoK-α expression impairs only EOC but not normal ovarian cells, thus supporting the hypothesis that {"}cholinic phenotype{"} is a peculiar feature of transformed cells and indicating ChoK-α targeting as a novel approach to improve efficacy of standard EOC chemotherapeutic treatments.",
keywords = "Antioxidant defense, Choline kinase, Ovarian cancer, Phosphocholine metabolism, Reversal of drug resistance",
author = "Marina Bagnoli and Anna Granata and Roberta Nicoletti and Balaji Krishnamachary and Bhujwalla, {Zaver M.} and Rossella Canese and Franca Podo and Silvana Canevari and Egidio Iorio and Delia Mezzanzanica",
year = "2016",
month = "6",
doi = "10.3389/fonc.2016.00153",
volume = "6",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - Choline metabolism alteration

T2 - Frontiers in Oncology

AU - Bagnoli,Marina

AU - Granata,Anna

AU - Nicoletti,Roberta

AU - Krishnamachary,Balaji

AU - Bhujwalla,Zaver M.

AU - Canese,Rossella

AU - Podo,Franca

AU - Canevari,Silvana

AU - Iorio,Egidio

AU - Mezzanzanica,Delia

PY - 2016/6/22

Y1 - 2016/6/22

N2 - Compared with normal differentiated cells, cancer cells require a metabolic reprograming to support their high proliferation rates and survival. Aberrant choline metabolism is a fairly new metabolic hallmark reflecting the complex reciprocal interactions between oncogenic signaling and cellular metabolism. Alterations of the involved metabolic network may be sustained by changes in activity of several choline transporters as well as of enzymes such as choline kinase-alpha (ChoK-α) and phosphatidylcholine-specific phospholipases C and D. Of note, the net outcome of these enzymatic alterations is an increase of phosphocholine and total choline-containing compounds, a "cholinic phenotype" that can be monitored in cancer by magnetic resonance spectroscopy. This review will highlight the molecular basis for targeting this pathway in epithelial ovarian cancer (EOC), a highly heterogeneous and lethal malignancy characterized by late diagnosis, frequent relapse, and development of chemoresistance. Modulation of ChoK-α expression impairs only EOC but not normal ovarian cells, thus supporting the hypothesis that "cholinic phenotype" is a peculiar feature of transformed cells and indicating ChoK-α targeting as a novel approach to improve efficacy of standard EOC chemotherapeutic treatments.

AB - Compared with normal differentiated cells, cancer cells require a metabolic reprograming to support their high proliferation rates and survival. Aberrant choline metabolism is a fairly new metabolic hallmark reflecting the complex reciprocal interactions between oncogenic signaling and cellular metabolism. Alterations of the involved metabolic network may be sustained by changes in activity of several choline transporters as well as of enzymes such as choline kinase-alpha (ChoK-α) and phosphatidylcholine-specific phospholipases C and D. Of note, the net outcome of these enzymatic alterations is an increase of phosphocholine and total choline-containing compounds, a "cholinic phenotype" that can be monitored in cancer by magnetic resonance spectroscopy. This review will highlight the molecular basis for targeting this pathway in epithelial ovarian cancer (EOC), a highly heterogeneous and lethal malignancy characterized by late diagnosis, frequent relapse, and development of chemoresistance. Modulation of ChoK-α expression impairs only EOC but not normal ovarian cells, thus supporting the hypothesis that "cholinic phenotype" is a peculiar feature of transformed cells and indicating ChoK-α targeting as a novel approach to improve efficacy of standard EOC chemotherapeutic treatments.

KW - Antioxidant defense

KW - Choline kinase

KW - Ovarian cancer

KW - Phosphocholine metabolism

KW - Reversal of drug resistance

UR - http://www.scopus.com/inward/record.url?scp=84982854094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982854094&partnerID=8YFLogxK

U2 - 10.3389/fonc.2016.00153

DO - 10.3389/fonc.2016.00153

M3 - Short survey

VL - 6

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - JUN

M1 - 153

ER -